Upcoming biological therapies in systemic lupus erythematosus.
Int Immunopharmacol
; 27(2): 189-93, 2015 Aug.
Article
en En
| MEDLINE
| ID: mdl-26028152
ABSTRACT
Systemic lupus erythematosus (SLE) is a chronic autoimmune condition with unpredictable course, intermingled with flares and periods of remission. Although the prognosis of the disease has improved in the past decades, current therapies are still associated with treatment-related complications. Recently, there has been major progress in the understanding of the pathogenesis of SLE, paving the way for the development of new biological agents, potentially revolutionizing the treatment of SLE. This review summarizes available data on novel biological therapies for SLE, focusing on recent results from clinical trials. As a result of treatment strategies based upon an individualized therapeutic approach, it is hoped that the clinical view of SLE will change from a severe autoimmune disease to a condition in which significant damage, mortality and treatment related complications can be prevented in the majority of SLE patients.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Productos Biológicos
/
Lupus Eritematoso Sistémico
Idioma:
En
Revista:
Int Immunopharmacol
Año:
2015
Tipo del documento:
Article
País de afiliación:
Reino Unido